Novo Nordisk(NVO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, Novo Nordisk achieved a 10% sales growth and a 6% operating profit growth, with obesity care sales increasing from DKK 6 billion in 2019 to DKK 82 billion in 2025 [4][10] - The gross margin decreased to 81% from 84.7% in 2024, influenced by amortizations and restructuring costs [34] - Operating profit decreased by 1% in DKK but increased by 6% at constant exchange rates, reflecting higher sales and distribution costs [34][35] Business Line Data and Key Metrics Changes - GLP-1 sales in diabetes increased by 6%, with U.S. operations growing by 5% and international operations by 7% [10] - Obesity care sales surged by 31%, with U.S. operations growing by 15% and international operations by 73%, primarily driven by Wegovy [10][11] - Rare disease sales increased by 9%, with U.S. operations growing by 7% and international operations by 10%, mainly due to the uptake of Sogroya [11] Market Data and Key Metrics Changes - The global GLP-1 market grew over 30% in 2025, with Novo Nordisk maintaining a 62% volume market share in GLP-1 products [10][12] - Wegovy sales reached DKK 28 billion in 2025, growing 134%, and was launched in 35 new countries [13] - In China, GLP-1 diabetes sales decreased by 5%, negatively impacted by wholesaler inventory movements [12] Company Strategy and Development Direction - Novo Nordisk is focusing on core therapeutic areas of obesity and diabetes, with plans to expand the obesity and diabetes markets through new online channels and partnerships [4][10] - The company aims to introduce new strategic aspirations at the Capital Markets Day in September 2026 [43][44] - The company is investing in expanding manufacturing capacity and R&D pipeline, with around DKK 60 billion allocated for manufacturing and DKK 30 billion for R&D [35][36] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant challenges in 2025 but emphasized resilience and commitment to meet unmet needs in diabetes, obesity, and rare diseases [43] - The 2026 guidance reflects expectations of pricing headwinds and a potential sales decline in U.S. operations, while anticipating continued growth in international operations [39][40] - The company expects to benefit from the Medicare Part D coverage for Wegovy starting mid-2026, but anticipates a gradual ramp-up in uptake [51][52] Other Important Information - Changes in the executive management team were announced, with new appointments for U.S. Operations and Product and Portfolio Strategy [6][9] - The company returned around DKK 52 billion to shareholders in dividends, marking the thirtieth consecutive year of increasing dividends per share [36][37] Q&A Session Summary Question: Guidance breakdown between volumes and price - Management explained that the U.S. sales decline is driven by price reductions and investments in market access, with expectations for volume growth despite lower prices [50][51] Question: Speed of Medicare unlock - Management anticipates a gradual ramp-up in Medicare Part D coverage for Wegovy, with limited benefits expected in 2026 and a larger impact in 2027 [52] Question: Changes in guidance from previous quarters - Management clarified that the guidance reflects the latest market trends and insights, including the encouraging early uptake of the Wegovy pill [58][59] Question: Supply risk for Wegovy pill - Management confirmed that they are monitoring supply levels closely to meet demand, especially given the strong launch of the Wegovy pill [83] Question: CagriSema and REDEFINE 4 trial insights - Management reiterated that REDEFINE 4 will provide insights into CagriSema's weight loss potential, with further data expected from REDEFINE 11 [78]